Recent News

Pilot Study of Rituximab Biosimilar in Newly Diagnosed CLL

Novel STAT3 Inhibitor Under Study in CLL

Does Idelalisib Increase the Risk of Bleeding Events in Patients With CLL?

Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update

Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL

FDA Brief: Rituximab Biosimilar Approved for Treatment of CLL

ASH 2020: 5-Year Update From MURANO on Venetoclax Versus Bendamustine in Resistant CLL

ASH 2020: Long-Term Update on Ibrutinib Plus Venetoclax in CLL

ASH 2020: PI3K Inhibitor Plus Monoclonal Antibody Versus Chemoimmunotherapy for CLL

ASH 2020: Early-Phase Study of Noncovalent BTK Inhibitor in CLL

ASH 2020: Phase II CAPTIVATE Study Update on Ibrutinib Plus Venetoclax in CLL

Case Report of COVID-19 Infection Unmasking CLL

Use of Ibrutinib During COVID-19–Induced Respiratory Failure in CLL: Case Study

Novel Mutation and CLL Resistance to BTK and SYK Inhibition: Case Study

Exploring Rapid Dose Escalation of Venetoclax in Patients With CLL

Personalizing Management of CLL: From the Advanced Practitioner Perspective

Can LCK Deletion Result in Acceleration of CLL?

Comparing Front-Line Treatments in CLL: Focus on Acalabrutinib

Adding Zanubrutinib to Obinutuzumab in CLL

Early Use of Lenalidomide With Pneumococcal Vaccine for High-Risk CLL

Genetic Landscape of CLL With IGH Translocations

SOHO 2020: Link Between WNT3 and LEF1 Expression Levels and Survival in CLL?

SOHO 2020: Interim Analysis of Real-World Registry of Elderly Patients With CLL

Managing CLL in the Era of COVID-19: Guidance From Global Experts

SOHO 2020: Debulking Regimens Prior to Venetoclax Therapy for CLL

SOHO 2020: Chemotherapy-Free Combination Therapy for CLL Under Study in Phase III Trial

Bendamustine Plus Rituximab in Older Patients With CLL: Swedish Real-World Study

Chemoimmunotherapy Regimen Under Study in Younger Patients With CLL

Case Report of Breast Involvement in a Male Patient With CLL

High-Risk CLL: Hematopoietic Stem Cell Transplantation Followed by Immune Intervention

Study Shows Benefit of Novel Agents for CLL With 17p Deletion

CLL and COVID-19: Large Italian Survey on Changes in Management

Case Report Features Potential Link Between JAK2 Inhibition and CLL

CLL and COVID-19: Treatment Lessons Learned

CLL and COVID-19: Continuity of Care in Italian Tertiary Hospital

FDA Clearance Granted for Assay for Monitoring Minimal Residual Disease in CLL

Dual PI3Kδ/CK1ε Inhibition on CLL T Cells

Predictors of Outcome in Patients with CLL and COVID-19

Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?

CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?